Global Market Size, Forecast, and Trend Highlights Over 2025-2037
Aortic Stenosis Treatment Market size was valued at USD 7.57 billion in 2024 and is expected to reach USD 24.63 billion by 2037, registering around 9.5% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of aortic stenosis treatment is assessed at USD 8.18 billion.
The growth of the market can be attributed to high prevalence of aortic stenosis, globally. It is the third most common cardiac diseases, after hypertension, and coronary heart disease. It occurs, when the aortic valve marrows, which creates pressure in the ventricle. Globally, aortic stenosis is present in 2.5-3% of the population above 75 years of age. Furthermore, the increasing investment in developing new treatment methods for valvular heart diseases is also expected to boost the market growth.
Aortic Stenosis Treatment Sector: Growth Drivers and Challenges
Growth Drivers
- Increasing Prevalence of Valvular Heart Diseases
- Rising Investment to Develop New Treatment Solutions
Challenges
- High Cost of Treatment
Aortic Stenosis Treatment Market: Key Insights
|
Base Year |
2023 |
|
Forecast Year |
2024-2036 |
|
CAGR |
9.5% |
|
Base Year Market Size (2023) |
USD 6.91 billion |
|
Forecast Year Market Size (2036) |
USD 22.48 billion |
|
Regional Scope |
|
Aortic Stenosis Treatment Aortic Stenosis Treatment Segmentation
The global aortic stenosis treatment market is segmented by treatment into aortic valve repair, balloon valvuloplasty, and others, out of which, the balloon valvuloplasty segment is anticipated to hold a notable share in the market during the forecast period owing to its application in treating infants and children, or adults who are too weak for valve replacement. On the basis of end-use, the aortic stenosis treatment market is segmented into hospitals, diagnostic center, and others, out of which, the hospitals segment is anticipated to garner the largest revenue, during the forecast period, as surgery is the only permanent treatment for aortic stenosis. Moreover, increasing patient pool of aortic stenosis, especially among the geriatric population, is estimated to boost the growth of the segment.
Our in-depth analysis of the global market includes the following segments
|
By Diagnosis |
|
|
By Treatment |
|
|
By End-User
|
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportAortic Stenosis Treatment Industry - Regional Synopsis
APAC Market Statistics
Regionally, the global aortic stenosis treatment market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. Asia Pacific industry is predicted to hold largest revenue share by 2037, on the back of high cases of valve diseases in the region.
North America Market Analysis
The aortic stenosis treatment market in the North America region is estimated to garner the largest share over the forecast period, owing to the efficient healthcare system, presence of major pharmaceutical companies in the region, and high investment in medical R&D activities. Moreover, increasing prevalence of aortic stenosis in developed countries, such as, the U.S. is estimated to boost the market growth. More than 5% of the population aged 85 years and above suffer from this disease in the U.S.
Companies Dominating the Aortic Stenosis Treatment Landscape
- Edwards Lifesciences Corporation
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- JenaValve Technology, Inc.
- Neovasc Inc.
- HighLife SAS
- Abbott Laboratories
- B. Braun Melsungen AG
- CryoLife Inc.
- Boston Scientific Corporation
- Medtronic PLC
- Siemens Healthcare GmbH
In the News
· May 18, 2021: Edwards Lifesciences Corporation announced the positive results of SAPIEN 3TAVR for patients with bicuspid aortic stenosis.
· December 15, 2021: Neovasc Inc. announced the completion of its first three Neovasc Reducer implants in France.
Author Credits: Radhika Pawar
- Report ID: 3125
- Published Date: Dec 24, 2024
- Report Format: PDF, PPT
